Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug

Novartis (NVS) announced that it will acquire Germany-based global biopharmaceutical company MorphoSys AG (MOR) to expand its oncology portfolio.Financial Terms of the AcquisitionNovartis will make a voluntary public takeover offer for all no-par value bearer shares of MorphoSys AG for €68 per share or an aggregate of €2.7 billion. The acquisition is expected to close in the first half of 2024.The transaction is contingent on customary closing conditions. This includes acceptance of the takeover offer by at ...